Search
Outlook Therapeutics Inc
OTLKAdd to Watchlist
1.450USD
-0.020-1.36%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
151.69MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.36%
5 Days
-15.20%
1 Month
+82.44%
6 Months
+119.70%
Year to Date
-8.23%
1 Year
-18.54%
Key Figures
1.498Open
1.630High
5.17MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
4.94%Turnover Ratio
1.470Prev. Close
1.430Low
6.03MTurnover
LossP/E Static
-5.23P/B
0.00%Div Yield TTM
-297.58%ROA
3.39052wk High
1.11Volume Ratio
-75.37MNet Profit
104.61MShares
-1.1289EPS TTM
0.86Beta
-827.71%ROE
0.16152wk Low
13.61%Amplitude
-17.18%Gross Margin
151.69MMarket Cap
10.65Reward/Risk
7.97%Risk Rate
TradingKey Stock Score of Outlook Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Outlook Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 184 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Outlook Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Outlook Therapeutics Inc Highlights
StrengthsRisks
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.41M.
Fairly Valued
The company’s latest PE is -1.28, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.06M shares, decreasing 27.30% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 10.16K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 2.57.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
5.500
Target Price
+274.15%
Upside Space
Outlook Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Outlook Therapeutics Inc Info
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Ticker SymbolOTLK
CompanyOutlook Therapeutics Inc
CEOJahr (Robert Charles)
Websitehttps://outlooktherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Outlook Therapeutics Inc (OTLK)?
The current price of Outlook Therapeutics Inc (OTLK) is 1.45.
What is the symbol of Outlook Therapeutics Inc?
The ticker symbol of Outlook Therapeutics Inc is OTLK.
What is the 52-week high of Outlook Therapeutics Inc?
The 52-week high of Outlook Therapeutics Inc is 3.39.
What is the 52-week low of Outlook Therapeutics Inc?
The 52-week low of Outlook Therapeutics Inc is 0.16.
What is the market capitalization of Outlook Therapeutics Inc?
The market capitalization of Outlook Therapeutics Inc is 151.69M.
Is Outlook Therapeutics Inc (OTLK) currently rated as Buy, Hold, or Sell?
According to analysts, Outlook Therapeutics Inc (OTLK) has an overall rating of Buy, with a price target of 5.50.
What is the Earnings Per Share (EPS TTM) of Outlook Therapeutics Inc (OTLK)?
The Earnings Per Share (EPS TTM) of Outlook Therapeutics Inc (OTLK) is -1.79.